[1] Baekkevold ES，Roussigne M，Yamanaka T，et al.Molecular characterization of NF-HEV，a nuclear factor preferentially expressed in human high endothelial venules [J]. Am J Pathol，2003，163(1):69-79. [2] Schmitz J，Owyang A，Oldham E，et al. IL-33，an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines [J]. Immunity，2005，23(5):479-490. [3] Roussel L，Erard M，Cayrol C，et al. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket [J]. EMBO Rep，2008，9(10):1006-1012. [4] Tominaga S.A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor [J]. FEBS Lett，1989，258(2):301-304. [5] Pei C，Barbour M，Fairlie-Clarke KJ，et al.Emerging role of interleukin-33 in autoimmune disease [J]. Immunology，2014，141(1):9-17. [6] Li XL，Lin TT，Qi CY，et al.Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis:associated with disease activity and vascular endothelial growth factor [J]. J Investig Med，2013，61(5):848-851. [7] Li GX，Wang S，Duan ZH，et al.Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis [J]. Scand J Rheumatol，2013，42(3):226-231. [8] Ciccia F，Alessandro R，Rizzo A，et al. Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis [J]. Rheumatology(Oxford)，2014，53(1):104-113. [9] Han GW，Zeng LW，Liang CX，et al.Serum levels of IL-33 is increased in patients with ankylosing spondylitis [J]. Clin Rheumatol，2011，3(12):1583-1588. [10] Chen T，Jia RZ，Guo ZP，et al. Elevated serum interleukin-33 levels in patients with Henoch-Sch?nlein purpura [J]. Arch Dermatol Res，2013，305(2): 173-177. [11] 李超，任立红，仰曙芬.过敏性紫癜患儿急性期血清白介素-33与抗内皮细胞抗体-IgA、抗心磷脂抗体-IgA相关性分析 [J]. 临床儿科杂志，2013，31（9）：833-836. [12] Ishikawa S，Shimizu M，Ueno K，et al. Soluble ST2 as a marker of disease activity insystemic juvenile idiopathic arthritis [J]. Cytokine，2013，62(2):272-277. [13] Palmer G，Talabot Ayer D，Lamacchia C，et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis [J]. Arth Rheum，2009.60(3):738-749. [14] Hu F，Shi L，Mu R，et al. Hypoxia-inducible factor-1α and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis [J]. PLoS One，2013，8(8):e72650. [15] Mok MY，Huanq FP，Ip WK，et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus [J]. Rheumatology(Oxford)，2010，49(3):520-527. [16] Yang Z，Liang Y，Xi W，et al. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population [J]. Clin Exp Med，2011，11(2):75-80. [17] Yu SL，Wong CK，Tam LS.The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus [J]. Expert Rev Clin Immunol，2013，9(8):739-749. [18] 赵林，袁琳，李晓琳，等.血清IL-33及可溶型受体ST2与原发性干燥综合征脏器受累的相关性分析 [J]. 细胞与分子免疫学杂志，2012，28(12):1311-1313. [19] Zhao L，Yao L，Yuan L，et al. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren’s Syndrome [J]. Cytokine，2013，64(1):22-24. [20] 孙海滨，王晓蕾，郁敏，等.急性免疫性血小板减少症患儿血清IL-33检测及其意义[J].现代免疫学，2012，32(6):306-509
